Clonidine half-life

The 12-hour input is an adult labeling estimate for parent clonidine.

Category: alpha-2-agonist · Updated: August 7, 2026

Sources and model notes are maintained by . This page is educational, not clinical guidance. Corrections: admin@halflifedb.co.

Model status12 hClonidine · day-scale representative value
Reported rangeNot displayedPublished when the current evidence record supports a readable range
Model scopeRelative declineNormalized first-order model, not an in-body concentration estimate
References2Linked studies, labels, reviews, or identity records described below
Relative starting point
100%

Every curve begins at 100%. No dose or measured body concentration is assumed.

0m12h24h36h2d2.5d0%25%50%75%100%X-axis: elapsed timeY-axis: amount remaining (%)

X-axis: elapsed time. Y-axis: modeled percentage of the relative starting point remaining. This is a mathematical visualization, not a personal concentration estimate.

Modeled remaining: 50.0%Half-life used: 12 h

Clonidine: evidence and interpretation notes

What the representative value means

The 12-hour input is an adult labeling estimate for parent clonidine. Renal function, age, formulation, and clinical use can all make a population-specific result differ from the simple curve.

For the interactive chart, HalfLifeDB starts with 12 hours as the representative value for Clonidine. Route, formulation, sampling, and metabolites remain attached to that label instead of being hidden inside the arithmetic.

Clonidine is included because half-life concepts are relevant beyond recreational or controlled substances. It is an alpha-2 agonist with direct medication-label context.

The 12 hour curve provides a representative view of how a once-present amount declines in a first-order model. It is not a blood pressure, withdrawal, or rebound-symptom predictor.

The citations are intentionally narrow: a DailyMed clonidine tablet label and the PubChem compound record.

Clinical use of clonidine depends on indication, dose form, patient factors, and monitoring. HalfLifeDB does not provide medication instructions.

For Clonidine, the curve should be kept separate from blood pressure response and rebound physiology. Pharmacodynamic effects can outlast or diverge from the modeled decline.

What each source contributes

  • DailyMed: Clonidine hydrochloride tablet. This product label adds formulation-specific pharmacokinetic context and does not represent every route or product.
  • PubChem: Clonidine. This identity record confirms names and compound identity and does not supply a human half-life.

For Clonidine, the numerical model is tied most closely to DailyMed: Clonidine hydrochloride tablet. As a product label, it adds formulation-specific pharmacokinetic context; it does not represent every route or product.

Why there is no range on the chart

This profile plots 12 hours for Clonidine without adding an unsourced high-low band. A single supported center is more honest than manufacturing a range from unrelated routes, populations, or formulations.

InterpretationReading the curve and its category context

Reading this curve

HalfLifeDB uses 12 h as a representative input for Clonidine. In the simplified model, about 25.0% remains after 24 hours and about 3% remains after five half-lives, or roughly 2.5 days.

This is a day-scale half-life. Repeated exposure, timing, and source context start to matter more than a single snapshot of the curve. The curve is relative: it does not estimate a person's measured concentration, effects, impairment, or time to clearance.

alpha-2 agonist context

Alpha-2 agonist interpretation often depends on formulation, central nervous system effects, blood-pressure context, and patient-specific clearance.

  • The curve is not a blood-pressure or sedation predictor.
  • Rebound, withdrawal, or clinical monitoring questions are outside the model.
  • Source context should be checked for product and route.
ComparisonTimeline checkpoints and nearby profiles

Clonidine timeline checkpoints

Elapsed timeModeled remainingReading note
12 h50.0%Meaningful modeled decline, not near-zero
24 h25.0%Long-tail portion of the model
2.0 days6.25%Low modeled remainder, not a clearance guarantee
3.0 days1.56%Low modeled remainder, not a clearance guarantee
5.0 days0.10%Low modeled remainder, not a clearance guarantee

Nearby profiles by half-life

These entries sit near Clonidine within the alpha-2 agonist group when sorted by representative half-life. That makes them curve comparisons, not statements about equal potency, effects, or risk.

No nearby published profiles are available in this category.

EvidencePharmacokinetic inputs and source trail

Pharmacokinetics at a glance

Representative half-life12 h
Curve typeNormalized, first-order decline

Selection note: The 12-hour input is an adult labeling estimate for parent clonidine. Renal function, age, formulation, and clinical use can all make a population-specific result differ from the simple curve.

Sources and evidence context

A linked record is not automatically proof of the displayed value. Study, labeling, review, and compound identity sources serve different purposes; notes below identify limitations when they are known.

0 PubMed0 PMC1 DailyMed1 PubChem
  1. Official labeling DailyMed label: Clonidine hydrochloride tablet.
    Official U.S. product labeling used for formulation and labeled pharmacokinetic context; its statements apply to the described product.
  2. Identity record PubChem Compound Summary: Clonidine.
    Compound identity and naming record. It supplies chemistry context, not independent numerical support for the model.
BoundariesWhat this page cannot answer and where to continue

What this page does not answer

  • It does not estimate impairment, intoxication, or fitness to drive.
  • It does not predict urine, blood, saliva, or hair test results.
  • It does not model repeated exposure, tolerance, withdrawal, or interactions.
  • It does not replace clinician, pharmacist, toxicologist, or emergency guidance.

Continue with context

Read the medical disclaimer, methodology, and research standards before using the model for comparison.